SCHEMBL4286396

SCHEMBL4286396

CC(C)(C)OCCN1CCC(CCO)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.48
CACNA1I Q9P0X4 1/20 0.48
HRH3 Q9Y5N1 3/20 0.42
ACHE P22303 2/20 0.42
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
LTA4H P09960 1/20 0.34
GNAO1 P09471 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
CYP1A2 P05177 1/20 0.33
ADRB2 P07550 1/20 0.33
CHRM2 P08172 1/20 0.33
HTR1A P08908 1/20 0.33
CYP2D6 P10635 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21673666 0.87 KCNH2 (0.48) KCNH2CACNA1IHRH3GNAO1DRD2
SCHEMBL29312972 0.82 KCNH2 (0.47) KCNH2CACNA1IHRH3ACHEGNAO1
SCHEMBL4376655 0.82 ACHE (0.44) KCNH2CACNA1IHRH3ACHE
SCHEMBL4296034 0.80 KCNH2 (0.45) KCNH2CACNA1IHRH3ACHELTA4H
SCHEMBL19958949 0.79 KCNH2 (0.45) KCNH2CACNA1IHRH3ACHEGNAO1
SCHEMBL824023 0.78 CARM1 (0.47) KCNH2CACNA1IHRH3ACHEMEN1
SCHEMBL18872031 0.78 KCNH2 (0.43) KCNH2CACNA1IHRH3ACHEGNAO1
SCHEMBL15199142 0.77 KCNH2 (0.46) KCNH2CACNA1ILTA4H
SCHEMBL1318049 0.77 SLC18A3 (0.46) KCNH2HRH3ACHEESR2LTA4H
SCHEMBL19958952 0.77 KCNH2 (0.52) KCNH2CACNA1IGNAO1CYP2D6ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463506-B1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES ASTRAZENECA AB (SE) 2009-10-21 EP disclosed
US-20090215770-A1 Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases ASTRAZENECA AB (SE) 2009-08-27 US disclosed
CN-100491372-C Substituted quinazoline derivatives as inhibitors of aurora kinase ASTRAZENECA AB (SE) 2009-05-27 CN disclosed
US-7402585-B2 Substituted quinazoline derivatives as inhibitors of aurora kinases ASTRAZENECA AB (SE) 2008-07-22 US disclosed
CN-1620296-A Substituted quinazoline derivatives as inhibitors of aurora kinases ASTRAZENECA AB (SE) 2005-05-25 CN disclosed
US-20050070561-A1 Substituted quinazoline derivatives as inhibitors of aurora kinases ASTRAZENECA AB (SE) 2005-03-31 US disclosed
EP-1463506-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES Astrazeneca AB (SE) 2004-10-06 EP disclosed
WO-2003055491-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES ASTRAZENECA AB (SE) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070561-A1 Substituted quinazoline derivatives as inhibitors of aurora kinases AURKC, AURKA, AURKB KCNH2 1638/4885CACNA1I 3726/4885HRH3 1050/4885
US-20090215770-A1 Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases AURKC, AURKA, AURKB KCNH2 1993/4885CACNA1I 3271/4885HRH3 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.